Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Yuping Shen
Innovent Biologics, Inc.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
45
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study
Number of pages: 27
Posted: 30 Nov 2023
Bin Lian
,
Juan Li
,
Lu Si
,
Zhihong Chi
,
Lili Mao
,
Xuan Wang
,
Bixia Tang
,
Xieqiao Yan
,
Siming Li
,
Li Zhou
,
Xiaoting Wei
, Yuping Shen,
Qun Guo
,
Shirui Zheng
,
Jun Guo
and
Chuanliang Cui
Beijing Cancer Hospital, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Innovent Biologics, Inc., Innovent Biologics, Inc., Innovent Biologics, Inc., Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads
45
(896,913)
View PDF
Download
Abstract:
CTLA-4, IBI310, Combination immunotherapy, Melanoma, Urothelial carcinoma
Feedback
